{{Use British English|date=September 2013}}
{{Use dmy dates|date=August 2017}}

{{Infobox company
| name             = GW Pharmaceuticals PLC
| logo             =
| caption          =
| type             = [[Public Limited Company]]
| traded_as        = {{NASDAQ|GWPH}}<br>{{LSE|GWP}}
| genre            = <!-- Only used with media and publishing companies -->
| fate             =
| predecessor      =
| successor        =
| foundation       = 1998
| founder          = Geoffrey Guy and Brian Whittle
| defunct          =
| location_city    =
| location_country = United Kingdom<ref>{{cite web|url=https://www.gwpharm.com/about-us/contact-us|title=GW Pharmaceuticals Ltd |date=17 August 2017}}</ref>
| location         = Cambridge
| area_served      =
| key_people       = [[Justin Gover]] {{small|(CEO)}}<ref>https://www.theguardian.com/business/2011/apr/17/gw-pharmaceuticals-justin-gover-cannabis-sativex-multiple-sclerosis?INTCMP=SRCH
The Observer, Sunday 17 April 2011)</ref>
| industry         = Pharmaceutical
| products         = Sativex®
| services         =
| revenue          = $33.8 million (2001)<ref>{{cite web|url=http://www.londonstockexchange.com/exchange/prices-and-markets/stocks/summary/company-summary.html?fourWayKey=GB0030544687GBGBXAMSM |title=Prices and markets Stocks of GW PHARM |publisher=Londonstockexchange.com |date=28 June 2001}}</ref>
| operating_income =
| net_income       =
| aum              = <!-- Only used with financial services companies -->
| assets           =
| equity           =
| owner            =
| num_employees    =
| parent           =
| divisions        = Biotechnology
| subsid           =
| homepage         ={{url|http://www.gwpharm.com/}}
| footnotes        =
| intl             =
}}
'''GW Pharmaceuticals''' is a British [[Biopharmaceutics|biopharmaceutical]] company known for its [[multiple sclerosis]] treatment product [[nabiximols]] (brand name, Sativex). Sativex is the first natural [[cannabis (drug)|cannabis]] plant derivative to gain market approval in any country.<ref>{{cite web| url=http://thechart.blogs.cnn.com/2010/06/21/worlds-first-cannabis-drug-on-sale-in-uk/?iref=allsearch/ |title=World's first fully approved cannabis drug on sale in UK |author= Elizabeth Landau |publisher=Thechart.blogs.cnn.com |date=21 June 2010}}</ref>  Another cannabis-based product, Epidiolex, for treatment of [[epilepsy]], underwent phase 3 clinical trials in 2015.<ref name=GWRaises>{{cite news |url= http://www.ft.com/cms/s/0/5b7d988a-795a-11e3-b381-00144feabdc0.html#axzz2qxJb6R1v |work= Financial Times | date= 9 January 2014 |title= GW raises nearly $90m to develop childhood epilepsy treatment |author= Ward, Andrew |accessdate= 20 January 2014}}</ref><ref>{{Cite web|title = GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome|url = http://globenewswire.com/news-release/2015/06/11/743833/10138079/en/GW-Pharmaceuticals-Initiates-Second-Phase-3-Pivotal-Study-of-Epidiolex-R-CBD-in-Lennox-Gastaut-Syndrome.html|accessdate = 20 September 2015|first = GW Pharmaceuticals|last = plc}}</ref>

==History==

===Background===
Doctors Geoffrey Guy and Brian Whittle founded GW Pharmaceuticals in 1998. That year they obtained a cultivation license from the United Kingdom [[Home Office]] and the [[Medicines and Healthcare products Regulatory Agency|MHRA]], allowing GW Pharmaceuticals to cultivate [[Cannabis (drug)|cannabis]] from seeds and clones to conduct scientific research concerning the [[medical cannabis|medicinal]] uses of the [[Cannabis|plant]].<ref>{{cite web|url=http://www.cannabisculture.com/articles/2919.html |title=GW Pharm responds to CC |author=Pete Brady |publisher=Cannabisculture.com |date=25 April 2003 |deadurl=yes |archiveurl=https://web.archive.org/web/20131112022520/http://www.cannabisculture.com/articles/2919.html |archivedate=12 November 2013 |df=dmy }}</ref><ref>{{cite book|url=https://books.google.com/books/about/Cannabis_in_Medical_Practice.html?id=1AWGDhIOvk0C&redir_esc=y |title=Cannabis in Medical Practice: A Legal, Historical, and Pharmacological Overview of the Therapeutic Use of Marijuana (Google eBook) |via=[[Google Books]]|date=}}</ref>
[[File:Cannabis sativa (Köhler).jpg|thumb|right|''Cannabis'' as illustrated in Köhler's book of medicinal plants from 1897]]

====HortaPharm====
In July 1998, GW Pharmaceuticals collaborated with HortaPharm B.V., a cannabis research and development business based in the Netherlands,<ref>{{cite web|url=http://www.genetics.org/content/163/1/335.full.pdf+html |title=The Inheritance of Chemical Phenotype in Cannabis sativa L.(HortaPharm B.V., 1075 VS, Amsterdam, The Netherlands and Instituto Sperimentale per le Colture Industriali, 40128 Bologna, Italy) |publisher=Genetics.org |date=1 January 2003}}</ref> founded by two expert [[horticulturists]] from California,<ref>{{cite web|url=http://fourtwentywiki.com/sam-the-skunkman |title=sam-the-skunkman [Four Twenty Wiki&#93; |publisher=Fourtwentywiki.com |date=16 August 2011}}</ref> [[Robert Connell Clarke]]<ref>{{cite web|url=https://www.google.ca/search?tbo=p&tbm=bks&q=inauthor:%22Robert+Connell+Clarke%22|title=inauthor:"Robert Connell Clarke" – Google Search|publisher=}}</ref> and [[David Paul Watson]], also known as 'Sam the Skunkman'.
<ref>{{cite web|url=http://www.bop.gov/iloc2/InmateFinderServlet?Transaction=NameSearch&needingMoreList=false&FirstName=david&Middle=&LastName=watson&Race=U&Sex=U&Age=&x=0&y=0 |title=(DAVID A WATSON 49366-018 55-White-M UNKNOWN NOT IN BOP CUSTODY) david watson aka SKUNKMAN |publisher=Bop.gov |date=}}</ref> HortaPharm grew medicinal strains for the Dutch government.<ref>{{cite journal|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736886/pdf/erp210.pdf |title=Seeds from the marijuana cultivar Skunk no. 1 were provided by HortaPharm BV (Amsterdam, The Netherlands) and imported under a US Drug Enforcement Administration (DEA) permit to a registered controlled substance research facility. |format=PDF | pmc=2736886 |pmid=19581347 |doi=10.1093/jxb/erp210 |volume=60 |year=2009 |journal=J. Exp. Bot. |pages=3715–26 | last1 = Marks | first1 = MD | last2 = Tian | first2 = L | last3 = Wenger | first3 = JP | display-authors = etal }}</ref><ref>{{cite web|url=http://www.gwpharm.com/23july1998.aspx |title=Details released of collaboration between GW Pharmaceuticals and HortaPharm medicinal cannabis |publisher=Gwpharm.com |date=}}</ref>
<ref>{{cite web|last=Breen |first=Bill |url=http://www.fastcompany.com/magazine/79/cannabis.html?page=0%2C0 |title=The Cannabis Conundrum |publisher=Fastcompany.com |date=1 February 2004}}</ref>
<ref>{{cite web|last=Breen |first=Bill |url=http://www.fastcompany.com/magazine/79/cannabiswatson.html?page=0%2C0 |title=Dr. Dope's Connection |publisher=Fastcompany.com |date=1 February 2004}}</ref>

==Marketed products==

===Sativex===
{{Main article|Nabiximols}}
''[[Nabiximols]]'' (trade name ''Sativex'') is a [[botanical drug]] that is a [[cannabis]] extract, administered as a mouth spray; it was approved in the UK in 2010  as a treatment for [[multiple sclerosis]] (MS) patients to alleviate [[neuropathic pain]], [[spasticity]], overactive bladder, and other symptoms.<ref>UK Medicines Online [http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=3919 Nabiximols]  Page accessed 3 February 2016</ref>

Nabiximols is made with two unknown [[Cannabis strains|''Cannabis'' strains]], and is extracted with [[ethanol]] and [[carbon dioxide]].<ref>{{cite web|url=http://www.patentstorm.us/patents/7344736/fulltext.html |title=Extraction of pharmaceutically active components from plant materials |publisher=Patentstorm.us |date=}}</ref><ref>{{cite web|url=http://americanindependent.com/179457/is-big-pharma-set-to-corner-the-american-market-on-medical-marijuana |title=Is Big Pharma set to corner the American market on medical marijuana? |publisher=Americanindependent.com |date=25 April 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20120722101501/http://americanindependent.com/179457/is-big-pharma-set-to-corner-the-american-market-on-medical-marijuana |archivedate=22 July 2012 |df=dmy }}</ref>

In 2011, GW Pharmaceuticals concluded a partnership with [[Bayer]] for the distribution of Sativex in the UK,<ref>{{cite web|url=http://www.gwpharm.com/GW%20and%20Bayer%20Announce%20Marketing%20Agreement%20on%20Pioneering%20New%20Cannabis-based%20Treatment.aspx |title=GWPharma – GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment |publisher=Gwpharm.com |date=30 September 2004}}</ref> and have an estimated annual production of 100 tons of medicinal cannabis since 2012.<ref>{{cite web|url=https://www.youtube.com/watch?v=-8UmqADV7D0 |title=Medical Cannabis Strains – Geoffrey Guy, MD (GW Pharmaceuticals, UK (Conference) |publisher=Youtube.com |date=23 February 2010}}</ref>

==Products in development==

===Epidiolex===
In 2015 GW Pharmaceutical initiated [[Phase 3 clinical trial]]s of an investigational [[cannabidiol]], Epidiolex, for treatment of two [[rare disease|orphan conditions]] in children – [[Dravet syndrome|Dravet]] and [[Lennox–Gastaut syndrome|Lennox-Gastaut]] syndromes.<ref>{{Cite web|url = http://medsnews.com/health/therapeutic-cannabis-for-children-a-possible-new-treatment-for-epilepsy/|title = Therapeutic Cannabis for children – a possible new treatment for epilepsy|date = 9 December 2015|access-date = 3 February 2016|website = Meds News|publisher = |last = Butticè|first = Claudio}}</ref>  GW also received [[FDA Fast Track Development Program|fast track]] designation from the US FDA for use of the drug candidate to treat newborns with epilepsy.<ref>Tony Quested for Business Weekly.  6 August 2015 [http://www.businessweekly.co.uk/news/local-sharewatch/fda-backs-cannabis-based-medicine-danger-newborns FDA backs cannabis-based medicine for in-danger newborns]</ref>

==See also==
* [[Tetrahydrocannabinol#Dronabinol|Dronabinol]]
* [[Marinol]]
* [[Nabilone]]
* [[Medical use of cannabis]]

==References==
{{reflist|colwidth=30em}}

==External links==
* [https://books.google.com/books/about/The_Medicinal_Uses_of_Cannabis_and_Canna.html?id=AznCzOxvrtwC The Medicinal Uses of Cannabis and Cannabinoids]
{{Pharmaceutical industry in the United Kingdom}}
{{Science and technology in the United Kingdom}}
{{Cannabis in the United Kingdom}}

[[Category:Bayer brands]]
[[Category:Pharmaceutical companies established in 1998]]
[[Category:1998 in cannabis]]
[[Category:Biotechnology companies of the United Kingdom]]
[[Category:Pharmaceutical companies of the United Kingdom]]
[[Category:Cannabis research]]
[[Category:Cannabis in the United Kingdom]]
[[Category:Companies listed on NASDAQ]]
[[Category:Companies listed on the London Stock Exchange]]
[[Category:Medicinal use of cannabis organizations]]
[[Category:Cannabis companies]]
[[Category:Biotechnology companies established in 1998]]
[[Category:1998 establishments in the United Kingdom]]